11 Best and Cheap Stocks to Buy Right Now
On October 3, Wharton professor and WisdomTree Chief Economist Jeremy Siegel joined CNBC for an interview to discuss the current and near-future outlook for the stock market.
Sanofi Aventis (SNY)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arjuna Capital Farnum Brown And Adam Seitchik | 54,040 | $2,550,688 | +86% | 0.63% |
| 2. | Bailard Inc Thomas Bailard | 27,056 | $1,277,043 | -7% | 0.03% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,035,254 | $143,263,986 | 0.25% | |
| 2. | 2,079,994 | $97,359,301 | 0.52% | |
| 3. | 576,811 | $27,225,479 | 0.04% | |
| 4. | 444,014 | $20,957,466 | 0% | |
| 5. | 393,877 | $18,590,994 | 1.05% |
News See All
Sanofi (SNY) Caps Cost of Any Insulin Product at $35 per Month; Berenberg Reaffirms Its Buy Rating
On September 29, Berenberg reaffirmed its Buy rating on Sanofi (NASDAQ:SNY) with a price target of EUR110.00, citing better returns from the company’s medication pipeline.
12 Best Widow and Orphan Stocks to Buy According to Analysts
According to Reuters, U.S. stock index futures increased on September 29.
12 Ridiculously Cheap Stocks to Buy According to Analysts
On September 25, Katie Stockton, founder and managing partner of Fairlead Strategies, joined CNBC for an interview to discuss the latest market signals to watch.
Sanofi (SNY) Fell on Tariff Uncertainty
Ariel Investments, an investment management company, released its “Ariel Global Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
11 Best Low Cost Stocks to Buy According to Analysts
On September 13, Courtney Garcia, Payne Capital Management senior wealth advisor, appeared in an interview on CNBC to discuss the markets.
Sanofi (SNY) Loses 9% as New Drug Candidate Appears Weaker Than Predecessor
Sanofi snapped a two-day winning streak on Thursday, shedding 9.14 percent to end at $45.33 apiece following the results of its drug candidate Amlitelimab that fell short of its predecessor’s benchmark...
Sanofi (SNY) Expands Pipeline Through Multi-Billion Acquisitions Despite Earnings Miss
The French multinational pharmaceutical and healthcare company, Sanofi (NASDAQ:SNY) focuses on discovering, developing, manufacturing, and marketing a variety of pharmaceutical products, vaccines, and...
Sanofi (SNY)’s Sarclisa Gets EMA Nod for Multiple Myeloma
Sanofi (NASDAQ:SNY) is a global biopharmaceutical company focused on innovative medicines and vaccines, with active efforts in oncology, immunology, and rare diseases.
11 Best Annual Dividend Stocks to Buy According to Hedge Funds
Stability without compromising the returns has become the priority in today’s market. The looming uncertainty has made dividend stocks a top choice for hedge funds seeking a similar balance.
Hedge Fund Resource Center Billionaire Hedge Funds
